ArticleMolecular pharmacology2018
Identification of Positive Allosteric Modulators of the D
Open access · bronzeAbstract read
In one paragraph
Article in Molecular pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Synthesis and systematic evaluation of four stereoisomers of BMS compound A enabled by a diastereoselective cyclopropanation on a chiral ketal intermediate.RSC advances · 2026Article
- Oral Dysbiosis and Neuroinflammation: Implications for Alzheimer's, Parkinson's and Mood Disorders.Microorganisms · 2026Review
- Virtual Compound Screening for Discovery of Dopamine D1 Receptor Biased Allosteric Modulators.Journal of chemical information and modeling · 2025Article
- A non-canonical mechanism of GPCR activation.Nature communications · 2024Article
- A chemogenetic approach for dopamine imaging with tunable sensitivity.Nature communications · 2024Article
- Review on allosteric modulators of dopamine receptors so far.Health science reports · 2024Article
- The Molecular Mechanism of Positive Allosteric Modulation at the Dopamine D1 Receptor.International journal of molecular sciences · 2023Article
- The molecular mechanism of positive allosteric modulation at the dopamine D1 receptor.bioRxiv : the preprint server for biology · 2023Article
- Identification and Characterization of ML321: A Novel and Highly Selective DACS pharmacology & translational science · 2023Article
- Allosteric Modulators of Dopamine DMolecules (Basel, Switzerland) · 2022Review
- The Impact of the Secondary Binding Pocket on the Pharmacology of Class A GPCRs.Frontiers in pharmacology · 2022Review
- Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the DMolecular pharmacology · 2021Article
- Cell specific photoswitchable agonist for reversible control of endogenous dopamine receptors.Nature communications · 2021Article
- Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine DMolecules (Basel, Switzerland) · 2021Article
- Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies.Clinical pharmacokinetics · 2021Article
- Development of pyrimidone D1 dopamine receptor positive allosteric modulators.Bioorganic & medicinal chemistry letters · 2021Article
- Insights into the Interaction of LVV-Hemorphin-7 with Angiotensin II Type 1 Receptor.International journal of molecular sciences · 2020Article
- Allosteric Modulators of G Protein-Coupled Dopamine and Serotonin Receptors: A New Class of Atypical Antipsychotics.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Polymer-Modified Carbon Fiber Microelectrodes for Neurochemical Detection of Dopamine and Metabolites.ECS transactions · 2020Article
- Targeting GPCR Signaling for Idiopathic Pulmonary Fibrosis Therapies.Trends in pharmacological sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Kathryn D LudermanMolecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland (K.D.L., J.L.C., R.B.F., M.S.-S., A.E.M., B.K.A.W., L.A.H., D.R.S.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland (N.S., M.F., S.T.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (T.J.F., J.R.L.); KU Specialized Chemistry Center, University of Kansas, Lawrence, Kansas (P.J., J.A., K.J.F.); and Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.A., K.J.F.).
Jennie L ConroyMolecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland (K.D.L., J.L.C., R.B.F., M.S.-S., A.E.M., B.K.A.W., L.A.H., D.R.S.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland (N.S., M.F., S.T.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (T.J.F., J.R.L.); KU Specialized Chemistry Center, University of Kansas, Lawrence, Kansas (P.J., J.A., K.J.F.); and Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.A., K.J.F.).
R Benjamin FreeMolecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland (K.D.L., J.L.C., R.B.F., M.S.-S., A.E.M., B.K.A.W., L.A.H., D.R.S.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland (N.S., M.F., S.T.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (T.J.F., J.R.L.); KU Specialized Chemistry Center, University of Kansas, Lawrence, Kansas (P.J., J.A., K.J.F.); and Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.A., K.J.F.).
Noel SouthallMolecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland (K.D.L., J.L.C., R.B.F., M.S.-S., A.E.M., B.K.A.W., L.A.H., D.R.S.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland (N.S., M.F., S.T.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (T.J.F., J.R.L.); KU Specialized Chemistry Center, University of Kansas, Lawrence, Kansas (P.J., J.A., K.J.F.); and Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.A., K.J.F.).
Marc FerrerMolecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland (K.D.L., J.L.C., R.B.F., M.S.-S., A.E.M., B.K.A.W., L.A.H., D.R.S.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland (N.S., M.F., S.T.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (T.J.F., J.R.L.); KU Specialized Chemistry Center, University of Kansas, Lawrence, Kansas (P.J., J.A., K.J.F.); and Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.A., K.J.F.).
Marta Sanchez-SotoMolecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland (K.D.L., J.L.C., R.B.F., M.S.-S., A.E.M., B.K.A.W., L.A.H., D.R.S.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland (N.S., M.F., S.T.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (T.J.F., J.R.L.); KU Specialized Chemistry Center, University of Kansas, Lawrence, Kansas (P.J., J.A., K.J.F.); and Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.A., K.J.F.).
Amy E MoritzMolecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland (K.D.L., J.L.C., R.B.F., M.S.-S., A.E.M., B.K.A.W., L.A.H., D.R.S.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland (N.S., M.F., S.T.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (T.J.F., J.R.L.); KU Specialized Chemistry Center, University of Kansas, Lawrence, Kansas (P.J., J.A., K.J.F.); and Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.A., K.J.F.).
Blair K A WilletteMolecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland (K.D.L., J.L.C., R.B.F., M.S.-S., A.E.M., B.K.A.W., L.A.H., D.R.S.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland (N.S., M.F., S.T.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (T.J.F., J.R.L.); KU Specialized Chemistry Center, University of Kansas, Lawrence, Kansas (P.J., J.A., K.J.F.); and Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.A., K.J.F.).
Tim J FyfeMolecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland (K.D.L., J.L.C., R.B.F., M.S.-S., A.E.M., B.K.A.W., L.A.H., D.R.S.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland (N.S., M.F., S.T.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (T.J.F., J.R.L.); KU Specialized Chemistry Center, University of Kansas, Lawrence, Kansas (P.J., J.A., K.J.F.); and Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.A., K.J.F.).
Prashi JainMolecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland (K.D.L., J.L.C., R.B.F., M.S.-S., A.E.M., B.K.A.W., L.A.H., D.R.S.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland (N.S., M.F., S.T.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (T.J.F., J.R.L.); KU Specialized Chemistry Center, University of Kansas, Lawrence, Kansas (P.J., J.A., K.J.F.); and Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.A., K.J.F.).
Steve TitusMolecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland (K.D.L., J.L.C., R.B.F., M.S.-S., A.E.M., B.K.A.W., L.A.H., D.R.S.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland (N.S., M.F., S.T.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (T.J.F., J.R.L.); KU Specialized Chemistry Center, University of Kansas, Lawrence, Kansas (P.J., J.A., K.J.F.); and Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.A., K.J.F.).
Lisa A HazelwoodMolecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland (K.D.L., J.L.C., R.B.F., M.S.-S., A.E.M., B.K.A.W., L.A.H., D.R.S.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland (N.S., M.F., S.T.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (T.J.F., J.R.L.); KU Specialized Chemistry Center, University of Kansas, Lawrence, Kansas (P.J., J.A., K.J.F.); and Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.A., K.J.F.).
Jeffrey AubéMolecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland (K.D.L., J.L.C., R.B.F., M.S.-S., A.E.M., B.K.A.W., L.A.H., D.R.S.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland (N.S., M.F., S.T.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (T.J.F., J.R.L.); KU Specialized Chemistry Center, University of Kansas, Lawrence, Kansas (P.J., J.A., K.J.F.); and Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.A., K.J.F.).
J Robert LaneMolecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland (K.D.L., J.L.C., R.B.F., M.S.-S., A.E.M., B.K.A.W., L.A.H., D.R.S.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland (N.S., M.F., S.T.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (T.J.F., J.R.L.); KU Specialized Chemistry Center, University of Kansas, Lawrence, Kansas (P.J., J.A., K.J.F.); and Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.A., K.J.F.).
Kevin J FrankowskiMolecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland (K.D.L., J.L.C., R.B.F., M.S.-S., A.E.M., B.K.A.W., L.A.H., D.R.S.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland (N.S., M.F., S.T.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (T.J.F., J.R.L.); KU Specialized Chemistry Center, University of Kansas, Lawrence, Kansas (P.J., J.A., K.J.F.); and Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.A., K.J.F.).
David R SibleyMolecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland (K.D.L., J.L.C., R.B.F., M.S.-S., A.E.M., B.K.A.W., L.A.H., D.R.S.); NIH Chemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland (N.S., M.F., S.T.); Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia (T.J.F., J.R.L.); KU Specialized Chemistry Center, University of Kansas, Lawrence, Kansas (P.J., J.A., K.J.F.); and Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (J.A., K.J.F.) sibleyd@ninds.nih.gov.
National Center for Advancing Translational Sciences · USNational Institutes of Health · USUniversity of North Carolina at Chapel Hill · USMonash University · AUUniversity of Kansas · US
Funding
Molecular And Pharmacological Studies Of Dopamine ReceptorsZIANS002263 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI SIBLEY, DAVID · 2009 to 2025
$37.4MUniversity of Kansas Specialized Chemistry CenterU54HG005031 · NHGRI · UNIVERSITY OF KANSAS LAWRENCE · PI AUBE, JEFFREY · 2008 to 2013
$21.5MNHGRI NIH HHS U54 HG005031
Abstract
The D
Indexed as
Allosteric RegulationAllosteric SiteAnimalsbeta-ArrestinsCHO CellsCricetulusCyclic AMPDopamineGTP-Binding ProteinsHEK293 CellsHumansReceptors, DopamineSignal Transductionbeta-ArrestinsCyclic AMPDopamineGTP-Binding ProteinsReceptors, Dopamine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.